{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:35Z","timestamp":1793805935170,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Committee","doi-asserted-by":"publisher","award":["RCYX20221008093032008"],"award-info":[{"award-number":["RCYX20221008093032008"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025A1515010257"],"award-info":[{"award-number":["2025A1515010257"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.06.002","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:17:25Z","timestamp":1784855845000},"page":"282-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification and validation of TP53\/p53 status as a prognostic marker in penile squamous cell carcinoma: Evidence from a cohort study and meta-analysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Zijian","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yepeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaowei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaishang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.06.002_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLO-BOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0002","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.euf.2021.11.008","article-title":"Glansectomy and reconstruction for penile cancer: a systematic review","volume":"8","author":"Pang","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0003","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.urolonc.2025.04.003","article-title":"Evaluating the role of Adjuvant therapy in improving outcomes for patients with lymph node-positive penile cancer following surgical management","volume":"43","author":"Garaz","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0004","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.eururo.2023.02.027","article-title":"European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 update","volume":"83","author":"Brouwer","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0005","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.2147\/CMAR.S206579","article-title":"Predictors of inguinal lymph node metastasis in penile cancer patients: a meta-analysis of retrospective studies","volume":"11","author":"Hu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0006","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","article-title":"Penile cancer","volume":"7","author":"Thomas","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0007","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clgc.2015.07.009","article-title":"A combination of cisplatin and 5-fluorouracil with a taxane in patients who underwent lymph node dissection for nodal metastases from squamous cell carcinoma of the penis: treatment outcome and survival analyses in neoadjuvant and adjuvant settings","volume":"14","author":"Nicolai","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0008","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0009","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13000-022-01273-w","article-title":"P53 Immunostaining pattern is a useful surrogate marker for TP53 gene mutations","volume":"17","author":"Sung","year":"2022","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2024.03.038","article-title":"Single-cell atlas of penile cancer reveals TP53 mutations as a driver of an aggressive phenotype, irrespective of human papillomavirus status, and provides clues for treatment personalization","volume":"86","author":"Elst","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100250","article-title":"Different mutational landscapes in Human papillomavirus\u2013Induced and Human papillomavirus\u2013Independent invasive penile squamous cell cancers","volume":"36","author":"Ermakov","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0012","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/modpathol.2017.26","article-title":"HPV-negative penile squamous cell carcinoma: disruptive mutations in the TP53 gene are common","volume":"30","author":"Kashofer","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102719","article-title":"P53 in penile squamous cell carcinoma: a pattern-based immunohistochemical framework with molecular correlation","volume":"15","author":"Trias","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0014","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.bjc.6602730","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"Harris","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0015","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jnci\/djy088","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration","volume":"110","author":"Sauerbrei","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0017","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/sim.1696","article-title":"A non-parametric procedure for evaluating treatment effect in the meta-analysis of survival data","volume":"23","author":"Moodie","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0018","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0019","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ccell.2025.03.023","article-title":"Neoadjuvant Toripalimab plus Nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell car-cinoma","volume":"43","author":"An","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0020","article-title":"Correlation between the evolution of somatic alterations during lymphatic metastasis and clinical outcome in penile squamous cell carcinoma","volume":"11","author":"Cao","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0021","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1464-410X.2008.07603.x","article-title":"Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma","volume":"102","author":"Guerrero","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0022","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/jclinpath-2011-200429","article-title":"Expression of P53, P21 and cyclin D1 in penile cancer: P53 predicts poor prognosis","volume":"65","author":"Gunia","year":"2012","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0023","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.pathol.2023.03.010","article-title":"Immune cell infiltration, tumour budding, and the P53 expression pattern are important predictors in penile squamous cell carcinoma: a retrospective study of 152 cases","volume":"55","author":"Hrudka","year":"2023","journal-title":"Pathology"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0024","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00345-013-1024-4","article-title":"The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection","volume":"31","author":"Liu","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-5347(05)64836-7","article-title":"P53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy","volume":"168","author":"Lopes","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0026","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1590\/s1677-5538.ibju.2018.0756","article-title":"External validation of nomogram to predict inguinal lymph node metastasis in patients with penile cancer and clinically negative lymph nodes","volume":"45","author":"Maciel","year":"2019","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0027","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0022-5347(05)65389-X","article-title":"Immunoexpression of P53 protein and proliferating cell nuclear antigen in penile carcinoma","volume":"167","author":"Martins","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0028","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-15-1004","article-title":"Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy","volume":"75","author":"McDaniel","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0029","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/PAS.0000000000000124","article-title":"Histologic and immunohistochemical assessment of penile carcinomas in a North American population","volume":"38","author":"Mentrikoski","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0030","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.clgc.2021.07.001","article-title":"P53 and P16ink4a As predictive and prognostic biomarkers for nodal metastasis and survival in A contemporary cohort of penile squamous cell carcinoma","volume":"19","author":"Mohanty","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae220","article-title":"Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study","volume":"30","author":"Monteiro","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.606122","article-title":"The biomarker potential of Caveolin-1 in penile cancer","volume":"11","author":"Panic","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0033","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3889\/oamjms.2019.219","article-title":"P53 and survival rate in penile cancer","volume":"7","author":"Prapiska","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0034","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.humpath.2011.06.013","article-title":"A clinical, pathologic, and molecular study of P53 and murine double minute 2 in penile carcinogenesis and its relation to prognosis","volume":"43","author":"Rocha","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0035","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1186\/s12885-022-10127-z","article-title":"A comprehensive analysis of penile cancer in the region with the highest worldwide incidence reveals new insights into the disease","volume":"22","author":"Teixeira J\u00fanior","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0036","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/PAS.0000000000002291","article-title":"P53 immunohistochemistry defines a subset of human papillomavirus-independent penile squamous cell carcinomas with adverse prognosis","volume":"48","author":"Trias","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.596261","article-title":"Copy number analysis reveal genetic risks of penile cancer","volume":"10","author":"Yu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0038","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.clgc.2015.12.019","article-title":"Clinical significance of P53 and P16(Ink4a) status in a contemporary North American penile carcinoma cohort","volume":"14","author":"Zargar-Shoshtari","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0039","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.juro.2010.03.145","article-title":"Development and evaluation of a nomogram to predict inguinal lymph node metastasis in patients with penile cancer and clinically negative lymph nodes","volume":"184","author":"Zhu","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1464-410X.2007.06908.x","article-title":"The prognostic significance of P53, ki-67, epithelial cadherin and matrix metalloproteinase-9 in penile squamous cell carcinoma treated with surgery","volume":"100","author":"Zhu","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0041","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"P53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0042","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrm4007","article-title":"P53 in survival, death and metabolic health: a lifeguard with a licence to kill","volume":"16","author":"Kruiswijk","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0043","doi-asserted-by":"crossref","first-page":"567","DOI":"10.21873\/anticanres.13149","article-title":"Association of CD31 and P53 with survival of ovarian cancer patients","volume":"39","author":"Rask","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0044","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.clgc.2012.12.009","article-title":"The role of P53 on survival of upper urinary tract urothelial carcinoma: a systematic review and meta-analysis","volume":"11","author":"Ku","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0045","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2018.10.015","article-title":"The prognostic value of P16 and P53 expression for survival after Vulvar cancer: a systematic review and meta-analysis","volume":"152","author":"Sand","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0046","doi-asserted-by":"crossref","DOI":"10.48101\/ujms.v129.10719","article-title":"Therapeutic targeting of TP53 nonsense mutations in cancer","volume":"129","author":"Strandgren","year":"2024","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0047","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.pathol.2024.11.006","article-title":"The prognostic value of P53 and ki-67 expression status in penile cancer: a systematic review and meta-analysis","volume":"57","author":"Sand","year":"2025","journal-title":"Pathology"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0048","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1200\/JCO.21.02506","article-title":"TP53 Sequencing and P53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial cancer: an NRG oncology\/gynecologic oncology group study","volume":"40","author":"Thiel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0049","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1080\/15384101.2016.1191257","article-title":"HPV-mediated inactivation of tumor suppressor P53","volume":"15","author":"Trav\u00e9","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.urolonc.2026.06.002_bib0050","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant P53: one name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes Dev"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:28:21Z","timestamp":1793802501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005624"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and validation of TP53\/p53 status as a prognostic marker in penile squamous cell carcinoma: Evidence from a cohort study and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}